#ILCN
What’s in store for #TTLC26? 🧬
The Conference Chairs share key programming highlights, breakthrough data to watch, and why this year’s meeting is one you won’t want to miss.

Get the preview in ILCN: bit.ly/3MoKSO4

#LCSM
February 13, 2026 at 7:26 PM
New insights from Dr. Stephen Liu in ILCN spotlight zenocutuzumab as a potential first-line option for patients with NRG1-positive cancers.
Explore the article: bit.ly/3O1A09h
Targeting NRG1 Fusions: A Potential Role for Zenocutuzumab as a First-Line Therapeutic Option - ILCN.org (ILCN/WCLC)
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.
bit.ly
February 9, 2026 at 4:31 PM
Tomasik and Dziadziuszko conclude their two-part ILCN series by highlighting unresolved clinical questions and future directions for integrating HA-PCI and SRS into SCLC practice. Essential reading for oncology care teams and researchers.
Read now: bit.ly/4qrMhRV
Stereotactic Radiosurgery for Established Brain Metastases: Prospective Evidence - ILCN.org (ILCN/WCLC)
In the conclusion of this two-part series, Drs. Tomasik and Dziadziuszko highlight unresolved questions and future directions for integrating HA-PCI and SRS into practice for SCLC.
bit.ly
February 6, 2026 at 10:47 PM
Patient advocate Kate Sinclair highlights the importance of compassion and clear communication in a new ILCN article.

Read her perspective now: bit.ly/49Fo303
The Importance of Compassion and Clear Communication: A Patient Advocate Perspective - ILCN.org (ILCN/WCLC)
Patient advocate Kate Sinclair shares why communication is one of the most important tools for improving the patient experience during their lung cancer journey.
bit.ly
January 22, 2026 at 7:33 PM
📰 ICYMI: New updates from the US FDA for risvutatug rezetecan and the subcutaneous amivantamab plus hyaluronidase-lpuj.

Read the latest in ILCN: bit.ly/3YCZPP3
In Brief for January 14, 2026 - ILCN.org (ILCN/WCLC)
The US FDA grants special designation to risvutatug rezetecan for SCLC and approves the subcutaneous formulation of amivantamab plus hyaluronidase-lpuj for EGFR+ NSCLC.
bit.ly
January 20, 2026 at 7:14 PM
Experts outline how #Poland aims to reduce #lungcancer mortality while addressing one of the nation’s most persistent health challenges: tobacco dependence.

Read more in ILCN: bit.ly/4qtSi1k
A Comprehensive Framework: Integrating Smoking Cessation into LCS - ILCN.org (ILCN/WCLC)
Experts outline how Poland aims to reduce lung cancer mortality while addressing one of the nation’s most persistent health challenges: tobacco dependence.
bit.ly
January 15, 2026 at 6:28 PM
Tomasik and Dziadziuszko highlight a shift in SCLC toward brain-sparing radiation that aims to improve disease control and protect cognitive function.

Explore their discussion on ILCN: bit.ly/4pB3esr
Modern Brain Radiotherapy in SCLC: Integrating Hippocampal Avoidance and Stereotactic Precision - ILCN.org (ILCN/WCLC)
Drs. Tomasik and Dziadziuszko discuss how the SCLC field is shifting toward brain-sparing techniques to maximize disease control, as well as cognitive preservation.
bit.ly
January 14, 2026 at 9:55 PM
New on #ILCN: IASLC Spotlight, Global Policy & Partnerships Committee!
Learn how global experts are shaping policies to improve lung cancer prevention, early detection, and access to care worldwide.
bit.ly/4jyCUhz
IASLC Spotlight: Global Policy and Partnerships Committee - ILCN.org (ILCN/WCLC)
In a Q&A with ILCN, Dr. Gilberto de Lima Lopes, Committee Chair, details how the committee is working to address the most significant global challenges in lung cancer care.
bit.ly
January 8, 2026 at 5:08 PM
Updated results from the IND227 trial show that adding pembrolizumab to platinum-pemetrexed chemotherapy improved overall survival by 24% vs chemotherapy alone in advanced pleural mesothelioma, as presented by Dr. Scott Laurie.

Read more in ILCN: bit.ly/4jkXYbe
Updated Analysis Confirms Adding Pembrolizumab to Chemotherapy Improves Survival in Mesothelioma - ILCN.org (ILCN/WCLC)
Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.
bit.ly
December 31, 2025 at 3:27 PM
#WCLC25 recap: Tarlatamab + anti-PD-L1 demonstrated OS benefit as 1L maintenance therapy after chemo-IO in ES-SCLC.

Learn more in ILCN: bit.ly/49czUCq
Tarlatamab With Anti-PD-L1 Demonstrates OS Benefit as First-Line Maintenance Therapy After Chemo-IO in ES-SCLC - ILCN.org (ILCN/WCLC)
Lead investigator Dr. Kelly Paulson said the combination demonstrated unprecedented overall survival with a manageable safety profile in this patient population.
bit.ly
December 29, 2025 at 8:34 PM
Angus Pratt’s impact reached far beyond the page. As an ILCN contributor and editorial group member, he elevated lung cancer conversations globally. His more than seven years of survival after diagnosis reflects the meaningful progress being made in lung cancer care. Read more: bit.ly/4b6WWgE
Recognized Throughout the Cancer Advocacy World for His Red Toque, Angus Pratt Brought Lung Cancer to the Fore in Many Arenas - ILCN.org (ILCN/WCLC)
A real-world example of the progress that has been made in lung cancer care, ILCN editorial group member and contributor Angus Pratt survived more than seven years after his lung cancer diagnosis.
bit.ly
December 29, 2025 at 5:30 PM
Join the International Land Conservation Network on Wednesday at 11 a.m. for a webinar featuring the Center for Large Landscape Conservation’s new report, "Integrating Wildlife Habitat Connectivity into Local Government Planning: Examples, Recommendations, and Resources for U.S. Towns and Counties."
December 16, 2025 at 12:24 AM
Dr. Mihaela Aldea discusses how the IASLC's recently published consensus statement defines core standards for MTBs in a new ILCN article.

Read now ➡️ bit.ly/3MoXhkv

#LCSM
IASLC Recommendations Define Core Standards for Molecular Tumor Boards - ILCN.org (ILCN/WCLC)
Lead author, Dr. Mihaela Aldea, discusses how the IASLC's recently published consensus statement could strengthen new and established molecular tumor boards.
bit.ly
December 12, 2025 at 8:42 PM
The ceremony will include remarks by Chandni Navalkha, Director of Conservation and Stewardship at the Lincoln Institute of Land Policy; Jim Levitt, former Director of the ILCN; Victoria Alonso Armanet, Executive Director of FTA; and other distinguished guests.
December 3, 2025 at 10:01 PM
Join the International Land Conservation Network (ILCN) to celebrate the winner of the 2025 Conservation Innovation Award, Fundación Tierra Austral (FTA), in a virtual award ceremony on Thursday, December 11 at 9 AM ET.
December 3, 2025 at 10:01 PM
7. new jack swing is back.. www.youtube.com/watch?v=ilcN...
Not Enough (feat. THEY.)
YouTube video by Lido - Topic
www.youtube.com
November 29, 2025 at 2:56 AM
🧬New data presented by Dr. Nan Bi shed light on ctDNA status to identify patients who would benefit from consolidation ICI.

Learn more in ILCN: bit.ly/3XaZ1Ab
Using Early ctDNA, Study Findings Inform Prognostic Model - ILCN.org (ILCN/WCLC)
New data presented by Dr. Nan Bi shed new light on ctDNA status to identify patients who would benefit from consolidation ICI and to predict survival outcomes.
bit.ly
November 24, 2025 at 2:07 AM
New evidence strengthens the connection between air pollution exposure and higher #lungcancer risk.

Emerging data highlights the urgent need to address environmental factors that impact lung health.

Read the full story on ILCN: bit.ly/4ooeJ6g

#LCSM #LungCancerAwarenessMonth
New Data Strengthen the Link Between Air Pollution Exposure and Increased Lung Cancer Risk - ILCN.org (ILCN/WCLC)
Researchers addressed the role of PM2.5 in lung cancer initiation and screening outcomes, as well as how genetic and air pollution scores can identify those at an increased risk.
www.ilcn.org
November 23, 2025 at 1:24 AM
#WCLC2025 recap: STAS is associated with poor prognosis in early-stage NSCLC, regardless of surgical approach.
Read the latest data from Dr. Yasushi Yatabe in ILCN: bit.ly/4nl8ijw

#LCSM
STAS is Associated with Poor Prognosis in Early-Stage NSCLC Regardless of Surgical Approach - ILCN.org (ILCN/WCLC)
JCOG0802/WJOG4607L data validate segmentectomy as non-inferior to lobectomy, regardless of the presence of STAS, Dr. Yasushi Yatabe said.
bit.ly
November 12, 2025 at 5:03 PM
At #WCLC2025, patient advocate Debra Montague unveiled new survey data showing serious communication challenges in lung cancer care.
Full story in ILCN: https://bit.ly/48MyLD8
#LCSM
Lost in Translation: Survey Reveals Critical Communication Gaps in Lung Cancer Care - ILCN.org (ILCN/WCLC)
Complex information and poor communication were identified as major obstacles to meaningful participation in decision-making, according to data presented by patient advocate Debra Montague.
bit.ly
October 28, 2025 at 2:54 PM
#WCLC25 recap: Dr. Jessica J. Lin explains how the ECOG-ACRIN E4512 results won't change clinical practice. Read why in a new ILCN article: http://bit.ly/3W1SPdd #lungcancer #research
Lessons from ECOG-ACRIN E4512: Could Limited Gains Lead to Positive Direction in Refining Adjuvant Therapy? - ILCN.org (ILCN/WCLC)
Discussant Dr. Jessica L. Lin said the results won't change clinical practice after Dr. David Gerber reported no differences in OS or DFS.
bit.ly
October 26, 2025 at 7:25 PM
New data from UK screening programs show that individuals up to age 80 who are surgically fit may derive a survival benefit from #lungcancer screening. A new ILCN article looks at findings from Dr. Patrick Goodley. Read now: http://bit.ly/471aKqR
Survival Benefit Found in Screening Surgically Fit Patients Up to Age 80 - ILCN.org (ILCN/WCLC)
Findings from Dr. Patrick Goodley suggest that older patients who can undergo surgery may achieve survival benefits similar to younger patients.
bit.ly
October 20, 2025 at 2:55 PM
New findings from the FANSS trial make a compelling case for expanding #lungcancer screening beyond smokers. Dr. Elaine Shum explains in a new ILCN article.
Read now: bit.ly/46R1l4T
New Data Warrant Broader Lung Cancer Screening Guidelines - ILCN.org (ILCN/WCLC)
Dr. Elaine Shum said the FANSS trial data confirm the feasibility of expanding screening to high-risk individuals with no smoking history.
bit.ly
October 15, 2025 at 3:53 PM